Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients
DOI:
https://doi.org/10.2340/actadv.v104.18348Keywords:
Alopecia totalis, Alopecia universalis, Hair loss, JAK inhibitor, Janus kinase inhibitor, TrichoscopyAbstract
Abstract is missing (Short communication)
Downloads
References
Fukuyama M, Ito T, Ohyama M. Alopecia areata: current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol 2022; 49: 19-36.
https://doi.org/10.1111/1346-8138.16207 DOI: https://doi.org/10.1111/1346-8138.16207
Harries M, Macbeth AE, Holmes S, Chiu WS, Gallardo WR, Nijher M, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol 2022; 186: 257-265.
https://doi.org/10.1111/bjd.20628 DOI: https://doi.org/10.1111/bjd.20628
Lee S, Kim BJ, Lee YB, Lee WS. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol 2018; 154: 1145-1151.
https://doi.org/10.1001/jamadermatol.2018.2312 DOI: https://doi.org/10.1001/jamadermatol.2018.2312
Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021; 6: 402.
https://doi.org/10.1038/s41392-021-00791-1 DOI: https://doi.org/10.1038/s41392-021-00791-1
Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK inhibitors for treatment of alopecia areata. J Invest Dermatol 2018; 138: 1911-1916.
https://doi.org/10.1016/j.jid.2018.05.027 DOI: https://doi.org/10.1016/j.jid.2018.05.027
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687-1699.
https://doi.org/10.1056/NEJMoa2110343 DOI: https://doi.org/10.1056/NEJMoa2110343
De Greef A, Thirion R, Ghislain PD, Baeck M. Real-life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1-year follow-up data. Dermatol Ther (Heidelb) 2023; 13: 2869-2877.
https://doi.org/10.1007/s13555-023-01030-x DOI: https://doi.org/10.1007/s13555-023-01030-x
Zhan J, Cao J, Chen F, Jin Y, Huang C. Real-data on the use of baricitinib in adolescents with severe alopecia areata. J Eur Acad Dermatol Venereol 2023; 10.1111/jdv.19121.
https://doi.org/10.1111/jdv.19121 DOI: https://doi.org/10.1111/jdv.19121
Moussa A, Eisman S, Sinclair RD, Bhoyrul B. Treatment of alopecia areata of the beard with baricitinib. J Am Acad Dermatol 2023; 88: 948-950.
https://doi.org/10.1016/j.jaad.2022.11.028 DOI: https://doi.org/10.1016/j.jaad.2022.11.028
Gargiulo L, Ibba L, Vignoli CA, Ferrucci SM, Mercuri SR, Malagoli P, et al. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J Dermatolog Treat 2023; 34: 2268764.
https://doi.org/10.1080/09546634.2023.2268764 DOI: https://doi.org/10.1080/09546634.2023.2268764
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines - Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004; 51: 440-447.
https://doi.org/10.1016/j.jaad.2003.09.032 DOI: https://doi.org/10.1016/j.jaad.2003.09.032
Piraccini BM, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen YF, et al. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat 2023; 34: 2227299.
https://doi.org/10.1080/09546634.2023.2227299 DOI: https://doi.org/10.1080/09546634.2023.2227299
Roest YBM, van Middendorp HT, Evers AWM, van de Kerkhof PCM, Pasch MC. Nail involvement in alopecia areata: a questionnaire-based survey on clinical signs, impact on quality of life and review of the literature. Acta Derm Venereol 2018; 98: 212-217.
https://doi.org/10.2340/00015555-2810 DOI: https://doi.org/10.2340/00015555-2810
Published
How to Cite
License
Copyright (c) 2024 Takafumi Numata, Ryokichi Irisawa, Miho Mori, Masaki Uchiyama, Kazutoshi Harada
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
